Option Care Health Inc. Common Stock (OPCH)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Option Care Health is a home-infusion provider serving patients outside hospitals, with 8,000 employees. In fiscal year 2025, the year ended 2025-12-31, revenue was $5.6B, up from $5.0B in fiscal year 2024, ended 2024-12-31, but net income slipped to $207.6M from $211.8M. Diluted EPS rose only to $1.27 from $1.23. In fiscal Q1 2026, ended 2026-03-31, revenue was $1.4B, net income $45.3M, and diluted EPS $0.29. That is a stalwart profile, not a fast grower. FairStock calls it STALWART because profits grew 10.4% a year over four years and revenue 13.2%, though the recent filings show uneven profit. The balance sheet has debt/equity of 1.01, while ROCE is just 6.17%, so the business is not earning extraordinary returns on capital. The Piotroski F-Score is 7/9, and ROE is 16%, which tells me it is profitable but not fortress-like. Free cash flow is genuine: trailing FCF is $303.8M, a 6.2% yield on the $4.9B market cap. Valuation is the rub. At the 2026-10-13 close of $31.10, FairStock's P/E is 23.56, P/B is 3.70, PEG is 3.51, and EV/EBITDA is 14.49. Its Graham Number is $15.80, leaving a -96.84% margin of safety. Altman Z is 2.43. A beta of 0.61 and 16% ROE are appealing, but Graham would ask what protects the buyer if growth stalls. I see a decent business at a demanding price.

In plain English: Option Care Health provides home and alternate-site infusion care, including antibiotics, nutrition support, and immune therapies. The business produces steady revenue and real cash, but profits have slipped and it carries meaningful debt. At $31.10, the price looks expensive compared with its earnings and conservative value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer